Reportedly, the awarded funds will be used to support the development of innovative drugs to repair and protect the nervous system in multiple sclerosis (MS).
The award will fund studies with compounds, related tolamotrigine, an approved epilepsy therapy, which some studies suggest also can protect nerve cells from damage. CenTRion will conduct research to determine the safety and efficacy of its original neuroprotective compounds in laboratory models of MS.
Timothy Coetzee, president of Fast Forward, said: “The promise of current research like that undertaken by CenTRion Therapeutics to change the MS landscape is exciting. It fuels the collaboration between Fast Forward and EMD Serono in advancing science in key areas of focus to speed the development of new therapies and innovations to benefit people living with MS.”